Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Katherine B. Knox, Lynne Clay, Kiersten Stuart-Kobitz & Darren Nickel. (2020) Perspectives on walking from people with multiple sclerosis and reactions to video self-observation. Disability and Rehabilitation 42:2, pages 211-218.
Read now
Read now
Rafael Arroyo González. (2018) A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. Expert Review of Neurotherapeutics 18:10, pages 785-791.
Read now
Read now
Babita Bisht, Warren G Darling, Emily C White, Kaitlin A White, E Torage Shivapour, M Bridget Zimmerman & Terry L Wahls. (2017) Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study. Degenerative Neurological and Neuromuscular Disease 7, pages 79-93.
Read now
Read now
Matthew F Sidovar, Brendan L Limone & Craig I Coleman. (2016) Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort. Patient Related Outcome Measures 7, pages 13-18.
Read now
Read now
Alberto Raggi, Venusia Covelli, Silvia Schiavolin, Chiara Scaratti, Matilde Leonardi & Michelle Willems. (2016) Work-related problems in multiple sclerosis: a literature review on its associates and determinants. Disability and Rehabilitation 38:10, pages 936-944.
Read now
Read now
Jennifer Smrtka, Theodore Brown & Greg Bjorklund. (2016) Loss of mobility and the patient burden of multiple sclerosis: expert opinion on relevance to daily clinical practice. Postgraduate Medicine 128:1, pages 145-151.
Read now
Read now
Mark Cascione, Daniel Wynn, Luigi M. Barbato, Linda Pestreich, Lesley Schofield & Kevin McCague. (2013) Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Journal of Medical Economics 16:7, pages 859-865.
Read now
Read now
Herbert R Henney$suffix/text()$suffix/text() & Andrew R Blight. (2012) Walking impairment in patients with multiple sclerosis – a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degenerative Neurological and Neuromuscular Disease 2, pages 53-64.
Read now
Read now
Joanna Sweetland, Eimi Howse & E. Diane Playford. (2012) A systematic review of research undertaken in vocational rehabilitation for people with multiple sclerosis. Disability and Rehabilitation 34:24, pages 2031-2038.
Read now
Read now
Oscar Fernandez, Thomas Berger, Hans-Peter Hartung & Norman Putzki. (2012) Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Review of Clinical Pharmacology 5:6, pages 649-665.
Read now
Read now
Sheryl R. Haut, E. Jay Bienen & Aaron Miller. (2012) Clinical overview of the seizure risk of dalfampridine
. Expert Opinion on Drug Safety 11:4, pages 651-657.
Read now
Read now
Craig I. Coleman, Diana M. Sobieraj & Lawrence N. Marinucci. (2012) Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. Current Medical Research and Opinion 28:1, pages 49-56.
Read now
Read now
Keith C Hayes. (2011) Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7, pages 229-239.
Read now
Read now
Hillel Panitch & Angela Applebee. (2011) Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opinion on Pharmacotherapy 12:10, pages 1511-1521.
Read now
Read now
Articles from other publishers (42)
Alisia Chen, Ekaterina An, Ellene Yan, David He, Aparna Saripella, Nina Butris, Jinny Tsang, Marina Englesakis, Jean Wong, Shabbir Alibhai & Frances Chung. (2023) Incidence of preoperative instrumental activities of daily living (IADL) dependence and adverse outcomes in older surgical patients: A systematic review and meta-analysis. Journal of Clinical Anesthesia 89, pages 111151.
Crossref
Crossref
Bruno Kusznir Vitturi, Alborz Rahmani, Guglielmo Dini, Alfredo Montecucco, Nicoletta Debarbieri, Paolo Bandiera, Mario Alberto Battaglia, Tommaso Manacorda, Benedetta Persechino, Giuliana Buresti, Michela Ponzio, Matilde Inglese & Paolo Durando. (2022) Spatial and temporal distribution of the prevalence of unemployment and early retirement in people with multiple sclerosis: A systematic review with meta-analysis. PLOS ONE 17:7, pages e0272156.
Crossref
Crossref
C Thrue, M Riemenschneider, LG Hvid, E Stenager & U Dalgas. (2020) Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains. Multiple Sclerosis Journal 27:10, pages 1477-1485.
Crossref
Crossref
Eman Allataifeh, Hanan Khalil, Khader Almhdawi, Alham Al-Shorman, Ziad Hawamdeh, Khalid El-Salem & Gonca Bumin. (2020) The clinical correlates of participation levels in people with multiple sclerosis. NeuroRehabilitation 47:2, pages 153-160.
Crossref
Crossref
Lorenzo G. Mantovani, Paolo Cozzolino, Paolo A. Cortesi & Francesco Patti. (2020) Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation 40:4, pages 319-326.
Crossref
Crossref
C.E.P. van Munster, L. Kaya, K.H. Lam, N.F. Kalkers, J. Killestein & B.M.J. Uitdehaag. (2020) Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making. Multiple Sclerosis and Related Disorders 38, pages 101489.
Crossref
Crossref
I.D. Stolyarov, A.M. Petrov & A.N. Boyko. (2020) Efficacy and safety of Kinezia (fampridine) in the complex therapy of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:11, pages 45.
Crossref
Crossref
Jerry S Wolinsky, Natalie J Engmann, Jinglan Pei, Ashish Pradhan, Clyde Markowitz & Edward J Fox. (2020) An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability. Multiple Sclerosis Journal - Experimental, Translational and Clinical 6:1, pages 205521732091193.
Crossref
Crossref
Larissa Gerhard, Diana S Dorstyn, Gregory Murphy & Rachel M Roberts. (2018) Neurological, physical and sociodemographic correlates of employment in multiple sclerosis: A meta-analysis. Journal of Health Psychology 25:1, pages 92-104.
Crossref
Crossref
E. Noseda Grau, G. Román, A. Díaz Compañy, G. Brizuela, A. Juan & S. Simonetti. (2019) Relevance of silica surface morphology in Ampyra adsorption. Insights from quantum chemical calculations. RSC Advances 9:8, pages 4415-4421.
Crossref
Crossref
Erica Visintin, Michela Tinelli & Panos Kanavos. (2019) Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries. Health Policy 123:2, pages 118-129.
Crossref
Crossref
B Polistena, F Spandonaro, R Capra, S Fantaccini, L Santoni, GB Zimatore & C Gasperini. (2019)
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri
®
PharmacoEconomics (TyPE) Study
. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031985295.
Crossref
Crossref
C. Bakirtzis, E. Konstantinopoulou, D.W. Langdon, E. Grigoriadou, F. Minti, I. Nikolaidis, M.K. Boziki, T. Tatsi, P. Ioannidis, T. Karapanayiotides, T. Afrantou, G. Hadjigeorgiou & N. Grigoriadis. (2018) Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study. Journal of the Neurological Sciences 395, pages 106-112.
Crossref
Crossref
Susan S Conroy, Min Zhan, William J CulpepperIIII, Walter RoyalIIIIII & Mitchell T Wallin. (2017) Self-directed exercise in multiple sclerosis: Evaluation of a home automated tele-management system. Journal of Telemedicine and Telecare 24:6, pages 410-419.
Crossref
Crossref
Amber Salter, Nina P Thomas, Tuula Tyry, Gary R Cutter & Ruth Ann Marrie. (2017) A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry. Multiple Sclerosis Journal 24:7, pages 951-962.
Crossref
Crossref
L. Ramió-Torrentà, J.C. Álvarez-Cermeño, R. Arroyo, B. Casanova-Estruch, O. Fernández, J.A. García-Merino, M.A. Hernández, G. Izquierdo, S. Martínez-Yélamos, J. Meca, E. Moral, J. Olascoaga, J.M. Prieto & A. Saiz. (2018) A guide to treating gait impairment with prolonged-release fampridine (Fampyra ® ) in patients with multiple sclerosis. Neurología (English Edition) 33:5, pages 327-337.
Crossref
Crossref
L. Ramió-Torrentà, J.C. Álvarez-Cermeño, R. Arroyo, B. Casanova-Estruch, O. Fernández, J.A. García-Merino, M.A. Hernández, G. Izquierdo, S. Martínez-Yélamos, J. Meca, E. Moral, J. Olascoaga, J.M. Prieto & A. Saiz. (2018) Guía de tratamiento del deterioro de la marcha con fampridina de liberación prolongada (Fampyra ® ) en pacientes con esclerosis múltiple. Neurología 33:5, pages 327-337.
Crossref
Crossref
Myla D Goldman, Melanie D Ward, Robert W Motl, David E Jones, John H Pula & Diego Cadavid. (2016) Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Multiple Sclerosis Journal 23:10, pages 1405-1414.
Crossref
Crossref
E. Jones, J. Pike, T. Marshall & X. Ye. (2016) Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US. BMC Health Services Research 16:1.
Crossref
Crossref
Katrina L. Williams, Nancy L. Low Choy & Sandra G. Brauer. (2016) Are Changes in Gait and Balance Across the Disease Step Rating Scale in Multiple Sclerosis Statistically Significant and Clinically Meaningful?. Archives of Physical Medicine and Rehabilitation 97:9, pages 1502-1508.
Crossref
Crossref
Emerson Sebastião, Brian M. Sandroff, Yvonne C. Learmonth & Robert W. Motl. (2016) Validity of the Timed Up and Go Test as a Measure of Functional Mobility in Persons With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation 97:7, pages 1072-1077.
Crossref
Crossref
Cecilie Fjeldstad, Gustavo Suárez, Michael Klingler, Herbert R. HenneyIIIIII, Adrian L. Rabinowicz & Gabriel Pardo. (2015) Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis. International Journal of MS Care 17:6, pages 275-283.
Crossref
Crossref
Andrew D Goodman, Francois Bethoux, Theodore R Brown, Randall T Schapiro, Ron Cohen, Lawrence N Marinucci, Herbert R HenneyIIIIII, Andrew R Blight, M Agius, BGW Arnason, FA Bethoux, CT BeverJrJr, JD Bowen, TR Brown, DW Dietrich, K Edwards, MS Freedman, M Freedman, NJ Kachuck, MD Kaufman, M Keilson, O Khan, LB Krupp, TP Leist, JW Lindsey, FD Lublin, MK Mass, D Mattson, D McGowan, R Naismith, C O’Connell, JJ Oger, H Panitch, MA Picone, KW Rammohan, RT Schapiro, SR Schwid, T Scott, C Short, BW Thrower, TL Vollmer, A Camac, JA Cooper, WF Chumley, A Cross, RT Dunnigan, JS Gitt, M Hillen, DR Jeffrey, BO Khatri, K Kresa-Reahl, S Moon, J Preiningerova, M Tullman, B Weinstock-Guttman & DR Wynn. (2015) Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis Journal 21:10, pages 1322-1331.
Crossref
Crossref
Arnaud Kwiatkowski, Jean-Pierre Marissal, Madani Pouyfaucon, Patrick Vermersch, Patrick Hautecoeur & Benoît Dervaux. (2014) Social participation in patients with multiple sclerosis: correlations between disability and economic burden. BMC Neurology 14:1.
Crossref
Crossref
Andrew R. Blight, Herbert R. HenneyIIIIII & Ron Cohen. (2014) Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the New York Academy of Sciences 1329:1, pages 33-44.
Crossref
Crossref
Ruggero Capra, Mario Alberto Battaglia, Antonio Gaudioso, Laura Lopes, Damiano Paolicelli, Marco Paoloni, Carlo Pozzilli, Valter Santilli, Claudio Solaro & Maria Trojano. (2014) The MoSt Project––More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. Journal of Neurology 261:3, pages 526-532.
Crossref
Crossref
Neasa Hogan, Maria Kehoe, Aidan Larkin & Susan Coote. (2014) The Effect of Community Exercise Interventions for People with MS Who Use Bilateral Support for Gait. Multiple Sclerosis International 2014, pages 1-8.
Crossref
Crossref
Jennifer Ruiz, Michele P. Labas, Elizabeth W. Triche & Albert C. Lo. (2013) Combination of Robot-Assisted and Conventional Body-Weight–Supported Treadmill Training Improves Gait in Persons With Multiple Sclerosis. Journal of Neurologic Physical Therapy 37:4, pages 187-193.
Crossref
Crossref
Patricia Kennedy. (2013) Impact of Delayed Diagnosis and Treatment in Clinically Isolated Syndrome and Multiple Sclerosis. Journal of Neuroscience Nursing 45:6, pages S3-S13.
Crossref
Crossref
Myla D. GoldmanRobert W. MotlJohn ScagnelliJohn H. PulaJacob J. SosnoffDiego Cadavid. (2013) Clinically meaningful performance benchmarks in MS. Neurology 81:21, pages 1856-1863.
Crossref
Crossref
Jennifer Freeman, Richard Walters, Wendy Ingram, Anita Slade, Jeremy Hobart & John Zajicek. (2013) Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures. Multiple Sclerosis Journal 19:12, pages 1632-1639.
Crossref
Crossref
Craig I. Coleman, Matthew F. Sidovar, Matthew S. Roberts & Christine Kohn. (2013) Impact of Mobility Impairment on Indirect Costs and Health-Related Quality of Life in Multiple Sclerosis. PLoS ONE 8:1, pages e54756.
Crossref
Crossref
James Pike, Edward Jones, Krithika Rajagopalan, James Piercy & Peter Anderson. (2012) Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurology 12:1.
Crossref
Crossref
M. Yildiz. (2012) The impact of slower walking speed on activities of daily living in patients with multiple sclerosis. International Journal of Clinical Practice 66:11, pages 1088-1094.
Crossref
Crossref
Bianca Weinstock-Guttman, Steven L. Galetta, Gavin Giovannoni, Eva Havrdova, Michael Hutchinson, Ludwig Kappos, Paul W. O’Connor, J. Theodore Phillips, Chris Polman, William H. Stuart, Frances Lynn & Christophe Hotermans. (2011) Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology 259:5, pages 898-905.
Crossref
Crossref
Belgüzar Kara & Cengiz Han Açıkel. (2012) Predictors of coping in a group of Turkish patients with physical disability. Journal of Clinical Nursing 21:7-8, pages 983-993.
Crossref
Crossref
C. Donzé & J. De Sèze. (2012) Spasticité et vie quotidienne dans la sclérose en plaques. Revue Neurologique 168, pages S51-S56.
Crossref
Crossref
Jeffrey A. Cohen & Alexander Rae-GrantJeffrey A. Cohen & Alexander Rae-Grant. 2012. Handbook of Multiple Sclerosis. Handbook of Multiple Sclerosis
61
81
.
Yann Mikaeloff. 2012. Handbook of Children with Special Health Care Needs. Handbook of Children with Special Health Care Needs
213
230
.
Nicholas G. LaRocca. (2011) Impact of Walking Impairment in Multiple Sclerosis. The Patient: Patient-Centered Outcomes Research 4:3, pages 189-201.
Crossref
Crossref
Michaela Coenen, Alarcos Cieza, Jenny Freeman, Fary Khan, Deborah Miller, Andrea Weise & Jürg Kesselring. (2011) The development of ICF Core Sets for multiple sclerosis: results of the International Consensus Conference. Journal of Neurology 258:8, pages 1477-1488.
Crossref
Crossref
Albert Lo. (2011) Lokomat Training to Improve Gait in Multiple Sclerosis and Freezing of Gait in Parkinson’s Disease. Topics in Spinal Cord Injury Rehabilitation 17:1, pages 66-69.
Crossref
Crossref